In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

  Bioscience Valuation's services help me to communicate the value of our business to various stakeholders, including investors.

Dr. Adi Hoess, CEO Affimed


Core Services
  Financial Valuation
  Commercial Assessment &

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

  Market Model
  R&D Risk Model
  Valuation Model

Core Services - R&D Risk Analysis

Bioscience Valuation's Assessment of R&D Strategy and Development Risk includes
  • R&D risk evaluation and comparison with benchmarks,
  • fine-tuning of R&D success probabilities
    based on
    - stage of development,
    - indication,
    - degree of innovation,
    - mode of action,
    - type of molecule,
  • optimization of the development plan using decision trees, comparison with alternative
    development scenarios,
  • calculation of expected value jumps once development milestones have been reached,
  • applying the 'value of perfect information' algorithm to inform investment decisions.
Core Services - R&D Productivity Increase

About 50% of all medical research findings may lead to wrong scientific conclusions, thus significantly contributing to preclinical & clinical attrition rates.

Source: Bioscience Valuation Analysis, based on Ioannidis (2005),
The Economist (2013)

R&D productivity can be increased by

  • comprehensive target validation,
  • enhanced statistical power of
    preclinical research,
  • improved clinical trial funding,
  • risk-sharing agreements,
  • optimization of clinical study design,
  • considering insights gained from real world evidence (e.g., patient reported outcomes),
  • engagement in personalized medicine.

A 'top 15' pharmaceutical company wishes to advance forecasting of resources, considering R&D attriton rates by indication and various other variables.

Bioscience Valuation implemented a stepwise adjustment taking advantage of benchmark attrition rates that allows a more detailed resource planning, with improved capacity utilization.

This website uses cookies to ensure you get the best experience on our website.
Privacy Policy